Business Context and Reporting Period
This Form 8-K is a current report filed by Anthem, Inc. (now Elevance Health, Inc.) on September 12, 2018. The filing serves as a Regulation FD disclosure regarding upcoming investor communications scheduled between September 12, 2018, and September 28, 2018.
Key Financial Metrics
The filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity figures for a specific period. Instead, it provides forward-looking earnings guidance for the full year 2018:
- Full Year 2018 Net Income Guidance: Greater than $14.20 per share.
- Unfavorable Items: Approximately $1.20 per share included in the net income guidance.
- Adjusted Net Income Guidance: Greater than $15.40 per share (excluding the unfavorable items).
Material Changes
The filing does not disclose material changes to financial results compared to prior periods. It explicitly states that the guidance does not include any adjustment items beyond those already reported in the Company's second quarter 2018 earnings release.
Guidance, Outlook, and Risks
Management intends to reaffirm the full-year 2018 net income guidance during the specified investor meetings. The filing includes an extensive list of risks and uncertainties that could cause actual results to differ from projections, including:
- Regulatory changes related to the Affordable Care Act (ACA).
- Trends in healthcare costs and utilization rates.
- Competitive pressures and pricing dynamics.
- Litigation risks, specifically the ongoing dispute with Cigna Corporation regarding their merger agreement, which could result in substantial costs and management distraction.
- Operational risks related to information systems, data privacy, and pharmacy benefit management agreements.
- Financial risks associated with outstanding indebtedness and potential downgrades in financial strength ratings.
Investor Verification Checklist
- Verify the specific nature and magnitude of the $1.20 per share in "net unfavorable items" referenced in the Q2 2018 earnings release.
- Monitor the status and potential financial impact of the litigation between Anthem and Cigna Corporation.
- Review the Company's Q2 2018 earnings release to confirm the baseline for the "no new adjustment items" statement.
- Assess the impact of ongoing regulatory changes to the ACA on future premium rates and enrollment.